Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

There is no fulltext present in this item.

Title:	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
Author(s):	Paul, C.; Griffiths, C.E.; Kerkhof, P.C.M. van de ; Puig, L.; Dutronc, Yves; Henneges, Carsten; Hollister, Kristin; Reich, K.
Publication year:	2019
Source:	Journal of the American Academy of Dermatology, vol. 80, iss. 1, (2019), pp. 70-+
ISSN:	0190-9622
DOI:	https://doi.org/10.1016/j.jaad.2018.06.039
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/201063
Display more details
Subject:	All institutes and research themes of the Radboud University Medical Center Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences
Organization:	Dermatology
Journal title:	Journal of the American Academy of Dermatology
Volume:	vol. 80
Issue:	iss. 1
Page start:	p. 70
Page end:	p. +